相似文献
1
Current and novel therapeutics in the treatment of systemic lupus erythematosus.
J Allergy Clin Immunol. 2011 Feb;127(2):303-12; quiz 313-4. doi: 10.1016/j.jaci.2010.12.1087.
2
[Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Med Clin (Barc). 2013 Dec 21;141(12):533-42. doi: 10.1016/j.medcli.2013.02.014. Epub 2013 Apr 23.
3
Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.
Curr Rheumatol Rep. 2011 Aug;13(4):308-16. doi: 10.1007/s11926-011-0186-6.
4
The biology behind the new therapies for SLE.
Int J Clin Pract. 2007 Dec;61(12):2113-9. doi: 10.1111/j.1742-1241.2007.01528.x.
5
Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i100-i113. doi: 10.1093/rheumatology/kew417.
6
Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE.
Nat Rev Rheumatol. 2014 Feb;10(2):71-2. doi: 10.1038/nrrheum.2013.203. Epub 2013 Dec 17.
7
Pediatric systemic lupus erythematosus in Thammasat University Hospital.
J Med Assoc Thai. 2010 Dec;93 Suppl 7:S283-93.
8
The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Autoimmun Rev. 2010 Dec;10(2):108-11. doi: 10.1016/j.autrev.2010.08.012. Epub 2010 Sep 8.
9
Diversity of neuropsychiatric manifestations in systemic lupus erythematosus.
Immunol Med. 2020 Dec;43(4):135-141. doi: 10.1080/25785826.2020.1770947. Epub 2020 May 27.
10
Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment.
Rheumatol Int. 2012 Dec;32(12):4061-3. doi: 10.1007/s00296-011-2130-5. Epub 2011 Sep 16.
引用本文的文献
1
Predictors of lethal outcome in patients with immunoinflammatory diseases hospitalized in the intensive care unit.
World J Crit Care Med. 2025 Sep 9;14(3):101890. doi: 10.5492/wjccm.v14.i3.101890.
2
Coexisting systemic lupus erythematosus with lupus nephritis and sickle cell trait: a case report of rare combination.
Ann Med Surg (Lond). 2025 May 21;87(6):3906-3910. doi: 10.1097/MS9.0000000000003291. eCollection 2025 Jun.
3
Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.
Arthritis Res Ther. 2024 Nov 18;26(1):201. doi: 10.1186/s13075-024-03435-1.
4
Implications of CD154 and Its Receptors in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.
Cells. 2024 Sep 28;13(19):1621. doi: 10.3390/cells13191621.
5
MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy.
Clin Exp Med. 2023 Dec;23(8):4065-4077. doi: 10.1007/s10238-023-01234-7. Epub 2023 Nov 3.
6
A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations.
Cureus. 2023 Aug 18;15(8):e43725. doi: 10.7759/cureus.43725. eCollection 2023 Aug.
7
Burn Management in a Patient With Acute Exacerbation of Comorbid Systemic Lupus Erythematosus.
Cureus. 2023 Aug 12;15(8):e43385. doi: 10.7759/cureus.43385. eCollection 2023 Aug.
8
Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
J Manag Care Spec Pharm. 2023 Sep;29(9):1010-1020. doi: 10.18553/jmcp.2023.29.9.1010.
9
Mesenchymal Stem Cells Suppress Dendritic Cells and Modulate Proinflammatory Milieu Through Interleukin-10 Expression in Peripheral Blood Mononuclear Cells of Human Systemic Lupus Erythematosus.
Acta Inform Med. 2023 Mar;31(1):20-25. doi: 10.5455/aim.2023.31.20-25.
10
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses.
Front Immunol. 2023 Mar 10;14:1043680. doi: 10.3389/fimmu.2023.1043680. eCollection 2023.
本文引用的文献
1
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Arthritis Res Ther. 2010;12(6):R204. doi: 10.1186/ar3179. Epub 2010 Nov 4.
2
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.
Nature. 2010 Jun 17;465(7300):937-41. doi: 10.1038/nature09102.
3
Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.
Arthritis Rheum. 2010 Jul;62(7):2086-92. doi: 10.1002/art.27452.
4
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.
Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221.
5
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.
6
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Arthritis Rheum. 2010 Jan;62(1):201-10. doi: 10.1002/art.27189.
7
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.
8
Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.
Lupus. 2009 Sep;18(10):884-8. doi: 10.1177/0961203309106921.
9
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Arthritis Rheum. 2009 Jun;60(6):1785-96. doi: 10.1002/art.24557.
10
Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.
J Clin Invest. 2009 Mar;119(3):504-11. doi: 10.1172/JCI36745. Epub 2009 Feb 9.
Zotero 插件